On a bustling afternoon on Thursday, just minutes past 3:00 p.m., an outpour of cheers erupted from the crowd-packed SINTEX Hall in Suwon Science College in Suwon, Gyeonggi Province.The applause and shouts nearly blew the speakers in the press room as the two-month-long managerial dispute within the
In the demanding terrain of pharmaceutical research and development (R&D), allegations from Rep. Kim Yeung-shik of the ruling People Power Party during the National Assembly's audit, scrutinizing Celltrion's Regkirona, its Covid-19 treatment, as an unsuccessful development, demands a balanced examin
The recent buzz in the Korean stock market revolves around the ambitious Cancer Moonshot Initiative, which aims to reduce the death rate from cancer by more than 50 percent over the next 25 years, propelled by U.S. President Joe Biden's administration.The interest in the Cancer Moonshot Initiative s
In the ever-competitive world of pharmaceuticals, it seems that every few years, a new company emerges touting its latest "miracle cure."This time, it's GemVax & KAEL, a Korean pharmaceutical company, that seems to have discovered the holy grail of medicine with their so-called wonder drug, GV-1001.
It's been 18 years since the tech-heavy Kosdaq stock market introduced the so-called “special listing system,” which helps unprofitable companies to be listed on the Kosdaq market under special circumstances.Biotech firms debuting on Kosdaq under this system usually present a rosy future during thei
The Korean offshoot of Eli Lilly has set about to expand insurance benefits for its CDK4/6 inhibitor, Verzenio (abemaciclib).Verzenio is a targeted agent used for HR+/HER2- (hormone receptor-positive/human epithelial cell growth factor receptor 2 negative) early breast cancer patients. It is the onl
There is a “good place to work,” which raised a question about its sustainability with hundreds of billions of won in debt and ordered employees to “rest” for refusing the early retirement program (ERP). Mundipharma Korea is that good workplace.Mundipharma Korea put its name on the “Good workplaces
In mid-January, President Yoon Suk-yeol went on a tour of the UAE and Switzerland, leading an economic mission. The business entourage, composed of major Korean companies, worked with President Yoon, meeting with the UAE government and business leaders.Medytox succeeded in setting the stage for its
The Korean biopharmaceutical industry is losing the trust of both retail and institutional investors quickly because many companies fail to keep their promises on new drug development.Some bio stocks, which once served as bellwethers on the tech-heavy Kosdaq, were recently pushed to the brink of del
Global Bio Conference (GBC) 2022 ended its three-day run on Wednesday.According to the conference organizers, the GBC, hosted by the Ministry of Food and Drug Safety (MFDS), aims to set the stage for active communication aiming to lead a balanced international regulatory environment.The conference p
“We cannot answer your question as we have to ask our global headquarters for comment and win their approval. Can you give us the question you want to ask in a document so we can ask our headquarters?”That was the response from a spokesperson for Janssen Korea, the local offshoot of Johnson & Johnso
The two leading presidential candidates and their camps exchanged verbal battles during the Lunar New Year holiday over foreign residents’ health insurance coverage.On Sunday, Yoon Suk-yeol, the standard-bearer of the conservative opposition People Power Party (PPP), said he would strengthen the reg
On Saturday night, Haeundae Beach, the major tourist spot in Busan, was in commotion as visitors set off firecrackers and held parties without wearing masks amid the Covid-19 pandemic.t turned out that the unrest was due to the rave party held by United States Forces Korea (USFK) and other foreigner
More than five months have passed since Korea began battling against the Covid-19 pandemic after confirming its first patient on Jan. 20.The new coronavirus’ outbreak has forced peoples to adjust to the new normal -- a term that implies that something previously abnormal has become commonplace – it also brought about various changes in the journalistic community.As a reporter specializ
The 2020 American Society of Clinical Oncology (ASCO) Annual Meeting completed its first online meeting last week.Despite its abrupt switch to an online format due to the global Covid-19 outbreak, the conference seems to have responded quite well to the change, publishing many noteworthy pieces of research.However, quite a few Korean biopharmaceutical companies said that the conference
The Korean biopharmaceutical companies have recently increased their presence in the global market by participating in world-renowned conferences and presenting their research results there.This year, for instance, Korean drug makers interacted with global companies and physicians by attending various events, including the American Society of Clinical Oncology (ASCO) meeting, European Leag
The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting was befitting of its reputation. Just the size of the McCormick Center, the venue of the conference, and the participants were enough to explain why ASCO is one of the leading medical conferences worldwide.It was not hard to feel a sense of pride regarding the strong presence of Korean researchers and professors at ASCO 2
The most shocking news in the biotech industry in the first half was the mislabeling of osteoarthritis therapy Invossa-K by Kolon Life Science.Physicians have used the treatment, trusting the data confirmed by the regulator after clinical trials. However, one of the drug ingredients has been mislabeled the whole time, appalling everyone – the drugmaker, the regulator, and patients. Mor
Recently, pharmaceutical companies have developed various biological agents for the treatment of inflammatory diseases.With more treatment options available other than the conventional tumor necrosis factor-alpha (TNF-α) inhibitors, the risk of developing tuberculosis has emerged as a major concern in the use of biological medicines.Experts say using TNF-α inhibitors for the first-line tre
“Please insert ‘severe’ in front of ‘acute pancreatitis’ in the headline and the main body of your English article.”Such request came from Samsung Bioepis to Korea Biomedical Review (KBR), the healthcare-focused English news outlet and the sister paper of the vernacular Korean Doctors’ Weekly. On Monday, the company released a press release announcing that it gained U.S. approval f
